UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 Commission File No. 001-33037 PRIMIS FINANCIAL CORP. (Exact name of registrant as specified in its charter) Virginia 20-1417448 (State or other jurisdiction (I.R.S. Employer Identification No.) of incorporation or organization) 1676 International Drive, Suite 900 McLean, Virg ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________ to ___________. Commission file number 001-38626 MESA AIR GROUP, INC. (Exact name of registrant as specified in its charter) NEVADA 85-0302351 (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (+61) 2 8330 6626 For the transition period from to Commission file number 001-42149 _________________________ Tamboran Resources Corporation (Ex ...

Exhibit 99.2 Anteris Announces Results for the First Quarter of 2025 MINNEAPOLIS, United States and BRISBANE, Australia 14 May 2025: Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 Highlights "Our foc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42540 Live Oak Acquisition Corp. V (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 61-2235506 (State or othe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33911 EMEREN GROUP LTD (Exact Name of Registrant as Specified in Its Charter) | British Virgin Islands | N/A | | --- | -- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from_______ to _______ Commission file number 001-40760 ATLANTIC INTERNATIONAL CORP. (Exact name of registrant as specified in its charter) Delaware 46-5319 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-38898 Applied Therapeutics, Inc. (Exact Name of Registrant as Specified in its Ch ...

Financial Performance - Net sales for Q1 2025 were $93,884,000, a decrease of 3.5% compared to $97,337,000 in Q1 2024[25] - Gross profit for Q1 2025 was $55,042,000, down from $58,306,000 in Q1 2024, reflecting a decline of 5.0%[25] - The company reported a net loss of $3,267,000 in Q1 2025, compared to a net income of $1,067,000 in Q1 2024[25] - Basic earnings per share for Q1 2025 were $(0.03), down from $0.01 in Q1 2024[25] - The net loss for the period ending March 31, 2025, was $3,267,000, compared to a net loss of $2,801,000 for the same period in the previous year, indicating a deterioration in financial performance[28] - For the three months ended March 31, 2025, the net loss was $3.267 million compared to a net income of $1.067 million for the same period in 2024, indicating a significant decline in profitability[31] - The company reported a net loss of $3.3 million for the three months ended March 31, 2025, which is a decline of 406.2% compared to a net loss of $1.1 million for the same period in 2024[96] - Adjusted EBITDA for the three months ended March 31, 2025, was $1.1 million, down 78.8% from $5.1 million for the same period in 2024[96] - The adjusted EBITDA margin for the three months ended March 31, 2025, was 1.1%, compared to 5.2% for the same period in 2024[96] Operating Expenses - Total operating expenses increased to $58,565,000 in Q1 2025, compared to $57,429,000 in Q1 2024, representing a rise of 1.98%[25] - Operating expenses increased by $1.1 million, or 2.0%, for the three months ended March 31, 2025, with operating expenses as a percentage of net sales rising by 340 basis points[115] Assets and Liabilities - Total current assets decreased to $197,956,000 as of March 31, 2025, from $211,413,000 as of December 31, 2024, a decline of 6.3%[20] - Total liabilities as of March 31, 2025, were $166,678,000, down from $171,863,000 at the end of 2024, a decrease of 3.0%[21] - Cash and cash equivalents decreased to $147,338,000 as of March 31, 2025, from $161,925,000 as of December 31, 2024, a decline of 9.0%[20] - The company’s total stockholders' equity decreased to $102,972,000 as of March 31, 2025, from $109,382,000 at the end of 2024, a decrease of 5.8%[22] - Current portion of long-term debt increased significantly to $20,000,000 as of March 31, 2025, compared to $5,688,000 at the end of 2024, an increase of 251.5%[21] - The company's total debt as of March 31, 2025, was $54.844 million, down from $56.063 million as of December 31, 2024[65] Cash Flow - The company reported a net cash used in operating activities of $7.127 million for Q1 2025, an increase from $5.790 million in Q1 2024[31] - Net cash used in investing activities was $0.7 million for the three months ended March 31, 2025, compared to $0.6 million in 2024, primarily due to increased purchases of property and equipment[140] - Net cash used in financing activities increased to $6.7 million in the first quarter of 2025 from $2.0 million in 2024, mainly due to higher tax distributions of $4.4 million[141] Shareholder Activities - The company repurchased 102,460 shares of common stock during the period, which is a strategic move to manage equity and enhance shareholder value[28] - The average price paid per share for the repurchases was $1.56, with the highest being $1.84 and the lowest at $1.47[165] - The Board of Directors approved a share repurchase program authorizing up to $20.0 million of Class A common stock purchases, effective until December 8, 2026[165] Revenue Recognition - The company recognized $17.6 million of revenue that was previously deferred as of December 31, 2024, compared to $16.2 million for the same period in 2024[54] - As of March 31, 2025, total deferred revenue was $23.1 million, an increase from $18.9 million as of December 31, 2024[53] Market and Economic Conditions - The current inflationary environment and changes in macro-level consumer spending trends have negatively impacted sales and could further affect operating results[106] - Net sales for the three months ended March 31, 2025, decreased by $3.5 million, or 3.5%, compared to the same period in 2024, primarily due to a 14.2% decrease in Average Order Value (AOV) despite a 12.4% increase in order volumes[111] Internal Controls and Compliance - The company has identified a material weakness in internal controls related to information technology general controls, which could impact financial reporting[155] - The company intends to remediate the identified material weakness through various measures, including hiring a director of ITGC and enhancing training and access management procedures[157]